[go: up one dir, main page]

TR201803451T4 - Olmesartan formülasyonlari. - Google Patents

Olmesartan formülasyonlari. Download PDF

Info

Publication number
TR201803451T4
TR201803451T4 TR2018/03451T TR201803451T TR201803451T4 TR 201803451 T4 TR201803451 T4 TR 201803451T4 TR 2018/03451 T TR2018/03451 T TR 2018/03451T TR 201803451 T TR201803451 T TR 201803451T TR 201803451 T4 TR201803451 T4 TR 201803451T4
Authority
TR
Turkey
Prior art keywords
olmesartan
formulations
pharmaceutically acceptable
acceptable salts
amlodipine
Prior art date
Application number
TR2018/03451T
Other languages
English (en)
Inventor
Söylemez Serdar
Farshi Ferhat
Avci Recep
Yildirim Ersi̇n
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of TR201803451T4 publication Critical patent/TR201803451T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, geliştirilmiş bir çözünme profili için olmesartan veya farmasötik olarak kabul edilebilir tuzları ve esterlerini veya kombinasyon halinde amlodipin veya farmasötik olarak kabul edilebilir tuzları gibi aktif farmasötik bileşen ve uygun yardımcı maddeleri içeren farmasötik bileşimleri sağlar
TR2018/03451T 2010-08-08 2011-08-08 Olmesartan formülasyonlari. TR201803451T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172244A EP2425859A1 (en) 2010-08-08 2010-08-08 Olmesartan formulations

Publications (1)

Publication Number Publication Date
TR201803451T4 true TR201803451T4 (tr) 2019-07-22

Family

ID=43242598

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/03451T TR201803451T4 (tr) 2010-08-08 2011-08-08 Olmesartan formülasyonlari.

Country Status (4)

Country Link
EP (2) EP2425859A1 (tr)
ES (1) ES2663721T3 (tr)
TR (1) TR201803451T4 (tr)
WO (1) WO2012020368A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2883539A1 (en) * 2013-12-12 2015-06-17 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of olmesartan and amlodipine
CN105663070A (zh) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 一种含有奥美沙坦酯的药物组合物及其制备方法
CN114191402A (zh) * 2022-01-17 2022-03-18 成都恒瑞制药有限公司 苯磺酸氨氯地平片制备方法
CN114609289B (zh) * 2022-02-24 2023-11-14 云南龙津康佑生物医药有限公司 一种奥美沙坦酯氨氯地平复方制剂中杂质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
CA2061607C (en) 1991-02-21 1999-01-19 Hiroaki Yanagisawa 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US20100119607A1 (en) * 2005-04-18 2010-05-13 Rubicon Research Pvt. Ltd. Bioenhanced compositions
CN101247832B (zh) 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
WO2007001065A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
US20100237530A1 (en) 2006-06-27 2010-09-23 Daiichi Sankyo Company, Limited Compressed preparation
KR20090027734A (ko) 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20100278909A1 (en) 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
WO2009110010A2 (en) * 2008-03-07 2009-09-11 Sun Pharmaceutical Industries Ltd. Stable oral dosage form

Also Published As

Publication number Publication date
EP2637695B1 (en) 2017-12-13
EP2425859A1 (en) 2012-03-07
WO2012020368A1 (en) 2012-02-16
ES2663721T3 (es) 2018-04-16
EP2637695A1 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CR20110110A (es) Composicion farmaceutica
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
PH12015501096A1 (en) Composition for immediate and extended release
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TR201100152A2 (tr) Amlodipin içeren efervesan bileşimler.
TR201002084A1 (tr) Oral yolla dağılan donepezil tablet formülasyonları ve hazırlama yöntemi
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
TR201008517A2 (tr) Olmesartan medoksomil içeren ilaç formülasyonu.